Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
What You Should Know About Risks in the Banking Sector
Caleb Silver, editor-in-chief of Investopedia, joined Cheddar News to explain the risks in the banking sector after the recent turmoil with Silicon Valley Bank and the news that Credit Suisse's biggest backer said it wouldn't provide further financial help.
Load More